EfficacyCV Risk ProtectionEMPA-REG Outcome TrialGuidelinesExpert's video CHAMPS Prescribing Information Previous Next Empagliflozin (JARDIANCE®) is proven to go beyond lowering A1C to reduce the risk of CV death for adults who have type 2 diabetes and heart disease EXPERT'S VIDEO Read more 1:28 Expert's Video Prof. Zieroth Starting on Empa for T2D patients to address HF risk Watch now Opens in new tab Read more 1:43 Expert's Video Prof. Zieroth Safety in HF with T2D Watch now Opens in new tab Read more 1:00 Prof. Melanie Davies on Early Initiation of Empagliflozin Watch now Opens in new tab Read more 1:14 Prof. Melanie Davies - T2D Guidelines Recommendation Watch now Opens in new tab Read more 1:40 Prof. Roger Chen on Early Initiation of Empagliflozin Watch now Opens in new tab Read more 3:39 Prof. Roger Chen on Empagliflozin as CRM Medication Watch now Opens in new tab Pagination Load More Home Metabolic Empagliflozin Expert's video
Read more 1:28 Expert's Video Prof. Zieroth Starting on Empa for T2D patients to address HF risk Watch now Opens in new tab